During Tuesday’s Current trade, Shares of Liberty Interactive Corp (NASDAQ:QVCA), gain 1.55% to $26.84.
QVC, the world’s leading video and ecommerce retailer, recently declared its official entry into France, with the launch of live television programming and ecommerce. QVC France, which launched online at QVC.fr with 46 brands in June, began its video programming distribution on August 1, and plans to offer nearly 300 international and French brands by the end of 2015.
French Shoppers Can Say ‘Bienvenue” to Favorite QVC Brands
QVC France customers can shop a variety of high-quality local brands they know and love, in addition to new-to-the-market brands from QVC’s global portfolio – all brought to life through storytelling by inventors, entrepreneurs, designers and QVC France program hosts. At this time, product categories comprise beauty, jewelry, apparel, home and accessories. Some popular QVC brands to be offered on QVC France comprise Elemis, Skechers, Diamonique® and bareMinerals®. QVC France customers will also enjoy QVC’s best find of the day, Recently’s Special Value, the first of which was bareMinerals.
Liberty Interactive Corporation, through its auxiliaries, engages in the video and on-line commerce industries in North America, Europe, and Asia. It markets and sells various consumer products primarily through live televised shopping programs, Websites, and mobile applications.
Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), inclined 1.45% to $7.36, during its current trading session.
Achillion Pharmaceuticals, Inc. (ACHN) declared that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102) on the pharmacokinetics of AL-335 in healthy volunteers.
This phase I study is an open-label, two-group study of simeprevir and odalasvir, a HCV NS5A inhibitor, on the pharmacokinetics of AL-335, a nucleotide-based HCV polymerase inhibitor. The primary objective of the study is to investigate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 when administered in combination to healthy volunteers.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections. The company’s drug candidates for treating chronic HCV infection comprise ACH-3102, a NS5A inhibitor, which accomplished Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor that is in Phase I clinical development; and Sovaprevir, a NS3 protease inhibitor, which accomplished Phase II clinical trial.
Cerner Corporation (NASDAQ:CERN), during its Tuesday’s current trading session gained 2.18% to $61.93.
Cerner, a global leader in health care technology, and CoverMyMeds, the nation’s leading electronic preceding authorization (ePA) platform, have declared a contract to integrate CoverMyMeds’ ePA within Cerner’s Millennium(R) EHR. The advanced functionality will provide more than 350,000 e-prescribing end users the ability to accelerate the prescription review process by removing manual processes and assist reduce transaction costs.
According to a 2012 study by the Center for Health Transformation, PA and other medication formulary requirements are noteworthycontributors to the cost of provider interaction with health plans, which exceeds $100 billion annually. The study also showed beyond the health care costs, PA requests can delay patient treatment and result in prescription abandonment.
Cerner Corporation designs, develops, markets, installs, hosts, and supports healthcare information technology, healthcare devices, hardware, and content solutions for healthcare organizations and consumers in the United States and internationally. The company offers Cerner Millennium architecture, which comprises clinical, financial, and administration information systems that allow providers to access an individual’s electronic health record at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front and back-office professionals, and consumers.
Finally, Royal Dutch Shell plc (ADR) (NYSE:RDS.B), gained 2.05%, to $50.88.
Royal Dutch Shell plc’s (RDS-B) capital comprises of 3,918,015,024 A shares and 2,440,410,614 B shares, each with equal voting rights. Royal Dutch Shell plc holds no ordinary shares in Treasury.
The total number of A shares and B shares in issue is 6,358,425,638 and this figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Royal Dutch Shell plc under the FSA’s Disclosure and Transparency Rules.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids. It also converts natural gas to liquids to provide fuels and other products; markets and trades natural gas; extracts bitumen from mined oil sands and converts it to synthetic crude oil; and generates electricity from wind energy. In addition, the company engages in manufacturing, supplying, and shipping crude oil; selling fuels, lubricants, bitumen, and liquefied petroleum gas (LPG) for home, transport, and industrial use; converting crude oil into a range of refined products, counting gasoline, diesel, heating oil, aviation fuel, marine fuel, lubricants, bitumen, sulphur, and LPG; producing and marketing petrochemicals, such as the raw materials for plastics, coatings, and detergents for industrial customers; and alternative energy business. Further, it trades hydrocarbons and other energy-related products; provides shipping services; and produces base chemicals comprising ethylene, propylene, and aromatics, in addition to intermediate chemicals, such as styrene monomer, propylene oxide, solvents, detergent alcohols, ethylene oxide, and ethylene glycol.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
